Bluensomycin is an aminocyclitol antibiotic obtained from cultures of Streptomyces verticillus. In vivo it has been found to be effective against experimental Staphylococcus aureus infections in mice. Preliminary tests against a variety of microorganisms of human origin revealed that bluensomycin inhibited S. aureus, Proteus mirabilis, Streptococcus (Group D), and Nocardia asteroides. Escherichia coil, Pseudomonas aeruginosa, Klebsiella pneumoniae, Candida albicans, and Aspergillus nidulans were insensitive to inhibition by bluensomycin.

Sulfaguanol (Enterocura), an antibacterial sulfanilamide drug that was used for patients with acute diarrhea

Ritiometan, an antibacterial agent, is marketed under the trade name Necyrane for the treatment of colds and rhinopharyngitis for adults and children over 30 months.

Tulathromycin A is a triamilide antibiotic. Exists as an equilibrium mixture of two isomeric forms, Tulathromycin A (90%) and B (10%). It acts by binding to a bacterial ribosome sub-unit thereby inhibiting protein synthesis. Tulathromycin mixture is indicated for the treatment of bovine and swine respiratory disease, infectious bovine keratoconjunctivitis, bovine foot rot (interdigital necrobacillosis). In one bovine respiratory disease field study, two calves treated with DRAXXIN (Tulathromycin mixture) exhibited transient hypersalivation. In one field study, one out of 40 pigs treated with DRAXXIN exhibited mild salivation that resolved in less than four hours. Cross resistance occurs with other macrolides. Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides.

Ribostamycin sulfate is an aminoglycoside-aminocyclitol antibiotic isolated from a streptomycete. It is an important broad-spectrum antibiotic with important use against human immunodeficiency virus and is considered a critically important antimicrobial by the World Health Organization. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit (some work by binding to the 50S subunit), inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, leaving the bacterium unable to synthesize proteins vital to its growth. Ribostamycin is usually used to treat sepsis, superficial skin infection, deep skin infection, lymphangitis/lymphadenitis, chronic pyoderma, osteomyelitis, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, pulmonary abscess, pyothorax, secondary infection in chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection, peritonitis, cholecystitis, dacryocystitis, keratitis (including corneal ulcer), otitis media, sinusitis and gnathitis. The most commonly reported adverse reactions include renal dysfunction, liver disorder and rash.

Exalamide is an antifungal agent developed in Japan.

Propicillin (Baycillin Mega) is this semisynthetic penicillin, analogous to penicillin V, was introduced in the early 1960s. Although it is better absorbed from the gastrointestinal tract, overall it is inferior to phenoxymethylpenicillin and phenoxyethylpenicillin because of its lower antibacterial activity. Propicillin is used by propicillin-susceptible pathogens in adults and adolescents from 14 years to treat mild to moderate bacterial infections. These include skin infections, ear, nose and throat infections (such as otitis media, sinusitis, tonsillitis, pharyngitis) and infections of the bronchi andlung inflammation. Moreover propicillin can for prevention and treatment of scarlet fever or against rheumatic fever are used (bacterial infection of the nose and throat). Even with tooth or jaw surgery the drug is used to treat an endocarditis endocarditis prevent. Its mechanism of action could be due to binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thus propicillin may inhibit the third and last stage of bacterial cell wall synthesis

Sitafloxacin hydrate (DU-6859a, Gracevit), a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections. This is a new quinolone oral antibacterial to inhibit DNA replication of bacteria at the time of infection, and shows antibacterial action. Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci. Sitafloxacin has also demonstrated activity against clinical isolates of Klebsiella pneumoniae (including about 67% of strains producing extended-spectrum, beta-lactamases and resistant to ciprofloxacin), Enterobacter cloacae, Pseudomonas aeruginosa with some activity against quinolone-resistant strains and Acinetobacter baumannii. The in vitro activity against anaerobes is comparable to imipenem or metronidazole. Sitafloxacin showed dual inhibitory activity against both enzymes: Streptococcus pneumoniae DNA gyrase and topoisomerase IV.

Abafungin is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses and onychomycosis. Abafungin acts through inhibition of transmethylation at the C-24 position of the sterol side chain, catalyzed by the enzyme sterol-C-24-methyltransferase. Abasol is a topical cream formulation of abafungin seeking approval in 2008 in European markets.